T. Maher (St. Albans (Hertfordshire), United Kingdom), F. Bonella (Düsseldorf, Germany)
Late Breaking Abstract - Effectiveness and tolerability of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF) from a large Italian practice cohort
C. Vancheri (Catania, Italy), A. Sebastiani (Rome, Italy), P. Rottoli (Siena, Italy), F. Luppi ( Modena, Italy), S. Harari (MIlan , Italy), A. Ghirardini (Monza, Italy), K. Kirchgaessler (Basel, Switzerland), S. Tomassetti (Forli, Italy)
|     |
BAL cell transcriptome predicts survival in IPF and can be used to gauge and model treatment effects interfering with the TGF-beta pathway
A. Prasse (Hannover, Germany), A. Carleo (Hannover, Germany), B. Jaeger (Hannover, Germany), J. Schupp (Yale University, United States of America), P. Rottoli (Siena University, Italy), W. Wuyts (Leuven University, Belgium), N. Kaminski (Yale University, United States of America)
| |
Synergistic Drug Combination of Nintedanib and Vardenafil Inhibits Fibrosis in AKR-2B Fibroblasts
M. Bourne (Rochester, United States of America), T. Kottom (Rochester, United States of America), A. Limper (Rochester, United States of America)
| |
CHIT1 is a novel therapeutic target in idiopathic pulmonary fibrosis (IPF): anti-fibrotic efficacy of OATD-01, a potent and selective chitinase inhibitor in the mouse model of pulmonary fibrosis
B. Dymek (Warsaw, Poland), P. Sklepkiewicz (Warsaw, Poland), M. Mlacki (Warsaw, Poland), A. Zagozdzon (Warsaw, Poland), R. Koralewski (Warsaw, Poland), M. Mazur (Warsaw, Poland), M. Paplinska-Goryca (Warsaw, Poland), P. Nejman-Gryz (Warsaw, Poland), M. Proboszcz (Warsaw, Poland), K. Gorska (Warsaw, Poland), M. Maskey-Warzechowska (Warsaw, Poland), N. Przysucha (Warsaw, Poland), R. Krenke (Warsaw, Poland), A. Golebiowski (Warsaw, Poland), P. Dobrzanski (Warsaw, Poland), K. Dzwonek (Warsaw, Poland)
| |
Molecular Markers of Telomere Dysfunction and Senescence are Common Findings in the Usual Interstitial Pneumonia Pattern of Lung Fibrosis
J. Lee (Aurora, United States of America), J. La (San Francisco, United States of America), S. Aziz (San Francisco, United States of America), R. Brownell (San Francisco, United States of America), K. Jones (San Francisco, United States of America), G. Green (San Francisco, United States of America), B. Elicker (San Francisco, United States of America), J. Golden (San Francisco, United States of America), M. Matthay (San Francisco, United States of America), J. Kukreja (San Francisco, United States of America), H. Collard (San Francisco, United States of America), P. Wolters (San Francisco, United States of America)
| |
A new Humanized Mouse Model for Idiopathic Pulmonary Fibrosis and Effects of Nintedanib Treatment
A. Prasse (Hannover, Germany), B. Jäger (Hannover, Germany), L. Plappert (Hannover, Germany), K. Kraus (Hannover, Germany), L. Wollin (Biberach, Germany)
| |
Development of pulmonary fibrosis in conditional Nedd4-2 deficient mice
D. Leitz (Heidelberg, Germany), J. Duerr (Heidelberg, Germany), D. Dvornikov (Heidelberg, Germany), M. Szczygiel (Heidelberg, Germany), P. Konietzke (Heidelberg, Germany), D. Rotin (Toronto, Canada), M. Wielpütz (Heidelberg, Germany), H. Kawabe (Göttingen, Germany), M. Beers (Philadelphia, United States of America), U. Klingmüller (Heidelberg, Germany), M. Mall (Heidelberg, Germany)
| |
Calcium-sensing receptor as a therapeutic target for pulmonary fibrosis
K. Wolffs (Cardiff, United Kingdom), B. Mansfield (Cardiff, United Kingdom), S. Scofield (Cardiff, United Kingdom), J. Ward (London, United Kingdom), C. Corrigan (London, United Kingdom), Y. Prakash (Rochester, United States of America), P. Kemp (Cardiff, United Kingdom), D. Riccardi (Cardiff, United Kingdom)
| |